Summary
GS:SFHS is a family-based genetic epidemiology study with DNA and socio-demographic and clinical data from about 24 000 volunteers across Scotland aged 18-98 years, from February 2006 to March 2011. Biological samples and anonymized data form a resource for research on the genetics of health, disease and quantitative traits of current and projected public health importance. Specific and important features of GS:SFHS include the family-based recruitment, with the intent of obtaining family groups; the breadth and depth of phenotype information, including detailed data on cognitive function, personality traits and mental health; consent and mechanisms for linkage of all data to comprehensive routine health-care records; and 'broad' consent from participants to use their data and samples for a wide range of medical research, including commercial research, and for re-contact for the potential collection of other data or samples, or for participation in related studies and the design and review of the protocol in parallel with in-depth sociological research on (potential) participants and users of the research outcomes. These features were designed to maximize the power of the resource to identify, replicate or control for genetic factors associated with a wide spectrum of illnesses and risk factors, both now and in the future.
government's genetics in health-care initiative and was funded to undertake the Scottish Family Health Study (SFHS). 1 Family-based population genetic studies are important because the increased kinship among subjects enables the measurement of heritability and study of parent-of-origin effects. They allow use of approaches such as long-range haplotype phasing, imputation of rare alleles and haplotypes and linkage mappings. These will be increasingly important as genetic epidemiological studies turn their attention to identifying quantitative trait loci carrying multiple rare variants, causal trait-associated variants and de novo gene mutations, facilitated by recent advances in the speed and cost-effectiveness of DNA sequencing. [2] [3] [4] This work has the potential not only to lead to the discovery of genetic variants associated with health, disease and response to treatment but also to contribute to discovery of important disease pathways leading to future biomarker development and drug discovery.
Participants came from across Scotland, with some family members from further afield. Scotland has a high prevalence of common conditions including coronary heart disease, stroke, cancer, chronic obstructive pulmonary disease (COPD), diabetes and mental illness. Furthermore, the population in Scotland is relatively static and stable, 5 providing an ideal population in which to measure heritable and lifestyle influences on disease. Life expectancy is rising but still lags behind the rest of the UK 6 and many other Western European countries. 5 The leading causes of chronic illness and premature death are likely to become more prevalent in coming decades with the ageing population. The Scottish government, therefore, identified four main health priorities: cancer, coronary heart disease, stroke and dementia. 7, 8 These and many other common diseases have complex aetiology, with genetic and environmental factors interacting to influence phenotype and disease expression.
Who is in the cohort?
The original protocol for GS:SFHS has been described previously.
1 A summary is presented here, with more details available on the study website (www. generationscotland.org).
Potential participants ('probands') were identified at random from those aged 35-65 years from the lists of collaborating general medical practices, and invited to participate and also to identify at least one first-degree relative aged at least 18 years who would also participate, and preferably more. In the UK, $96% of the population is registered with a general practitioner (GP), 9 so this approximates to a general population family sample. Initially , GPs in the Glasgow and Tayside areas of Scotland collaborated; the study was extended during 2010 to include Ayrshire, Arran and Northeast Scotland. The age range for probands was also broadened to 18-65 years at this time. Besides recruitment by invitation, volunteers were welcomed if they met the criteria (518 years, with at least one first-degree relative who could participate). A total of 21 476 participants attended a research clinic in Glasgow, Dundee, Perth, Aberdeen or Kilmarnock, having first completed a pre-clinic questionnaire (PCQ). A further 2484 postal participants who were unable to attend a clinic completed a PCQ and sent a saliva sample for DNA extraction, using an Oragene kit. 10 These methods of identification, approach and recruitment were developed in parallel with an extensive public consultation exercise, as were the consent form and the participant information leaflet (PIL). 11 They were all reviewed after further consultation with actual and potential participants. 12, 13 In total, 126 000 potential probands were invited to participate, and 12.3% of them volunteered and met the main study criteria. Not all were recruited, for practical reasons or because of inability to recruit family members. In total, 6665 of these probands completed appointments (overall response rate 5.3%), along with an additional 1288 individuals who volunteered without invitation, and 16 007 family members, giving a total of 23 960.
The sample was 59% female, with a wide range of ages and socio-demographic characteristics (Tables 1  and 2 ; Figure 1 ); 39% lived in areas with above average socio-economic deprivation in the Scottish index of multiple deprivation.
14 Most (87%) participants were born in Scotland and 96% in the UK or Ireland. Around 82% of the parents and 75% of the grandparents were also born in Scotland. Data are available on birthplaces by local council area for participants, parents and grandparents born in Scotland.
A shared family identity number was given to groups where each member was a first-degree relative of at least one other person. Mean family size (excluding 1400 singletons without any relations in the study) was 4.05 members; median was 3 (IQR 2-5). The largest family had 36 participating members, and participants were grouped in 5573 families ( Figure 2) .
Compared with the Scottish population, where recent data were available in comparable format, [15] [16] [17] [18] our sample was generally healthier and wealthier, with a different age-sex profile, though important similarities were apparent (Table 3) . Although not truly representative, the sample includes a wide range of socio-demographic and clinical features. The cohort size results in large amounts of data on participants from all socio-economic classes, with many or multiple disease traits (including extreme values) and identification of intensively matched control subjects. 
What has been measured?
In addition to the PCQ, multiple measures were taken at the clinic, and samples of blood and urine collected (or saliva, if insufficient blood could be obtained for DNA extraction). In total, DNA was successfully extracted from 98.1% of the participants. A summary of all data collected and their completeness is shown in Tables 1 and 2 . All measures were taken in a standard order by trained clinical staff, according to rigorous standard operating procedures (SOPs) based on best supported practice (available on request or at www. generationscotland.org). Before any data collection, participants signed 'broad' consent forms, 19 with appropriate discussion, permitting use of data and samples for 'future medical research into health, illness and medical treatment' without specifying this further. It was made clear in the consent form, PIL and discussion that such research would be subject to appropriate ethical review, but might also lead to patent development and commercialization. They were also invited to provide consent for linkage of their data and samples to routine data sets (including Figure 2 Family size of participating families. Families are groups in the study sharing a family identity number; a family identity number was given to groups where each member was a first-degree relative of at least one other person in the group. Singletons (1400) are excluded from this graph-most of these had relatives who were registered with the study but did not participate NHS data), and to be re-contacted in the future for possible participation in research. Minor revisions to the PCQ were introduced in 2009, and some additional instruments and questions included (as listed in Tables 1, 4 and 5); the period up to this was termed Phase 1 (n ¼ 9901), and the period thereafter Phase 2 (n ¼ 14 059). At the time of collection, the PCQ, clinic report form (CRF) and biological samples were given barcode labels with unique study identification codes. No personal identifying information was attached to any data or samples at any stage. Ethical approval for the study was given by the NHS Tayside committee on research ethics (reference 05/s1401/89). Governance of the study, including public engagement, protocol development and access arrangements, was overseen by an independent advisory board, established by the Scottish government.
Members in Study Families
Validated questionnaires included those for chronic pain severity, 20 and angina. 21 Among other clinical assessments, blood pressure (BP) and heart rate were recorded twice, an electrocardiogram (ECG) was taken and respiratory function was measured using forced expiratory volume in 1 s (FEV 1 ), forced vital capacity (FVC) and forced expiratory flow (FEF) 3Â each. All clinical participants were screened for a history of emotional and psychiatric disorders using the structured clinical interview for DSM-IV disorders (SCID); 21.7% screened positive and were invited to continue the interview that focused on mood disorders; of these, 88% completed the interview (19.0% of participants). Milder degrees of psychological distress were assessed using the general health questionnaire 28 (GHQ 28). 22 Individual domain scores gave information on (i) somatic symptoms, (ii) anxiety/insomnia, (iii) social dysfunction and (iv) severe depression. The personality traits of neuroticism and extraversion were assessed using the Eysenck personality questionnaire-revised. 23 In Phase 2, participants were asked to complete standard questionnaires on schizotypal personality (SPQ-B) 24 and mood disorders (MDQ), 25 and 1278 people also completed an impulsivity questionnaire (BIS-11). 26 The following domains of cognitive function were assessed: verbal declarative memory ( 29 and verbal ability (Mill Hill vocabulary test). 30 Finally, 1049 people were tested on four-choice reaction time (Deary-Liewald CRT test 31 ), introduced later in the study.
How often have they been followed up?
Although data collection was cross-sectional, GS:SFHS becomes a cohort as a result of the ability to link to routine NHS data (Table 6 ). Linkage is possible using the community health index (CHI) number, a unique identifying number allocated to every person in Scotland registered with a GP, and used for all NHS procedures (registrations, attendances, samples, prescribing and investigations). Full prescribing data are available for participants in the Tayside area dating back to January 1989, in Fife from March 2008, and from the Glasgow area from January 2010.
A study looking at cardiovascular risk and assessment of familial clustering of risk involved obtaining hospital admissions and prescribing data for 15 787 participants, by linkage to their NHS records. In June 2011, these participants were found to have had a total of 27 061 hospital admissions, involving 6347 unique patients, since January 1981. Among those living in Tayside and Fife (n ¼ 7315), a total including 3281 items. Detailed analysis of these data is underway. A further project linking study data with a range of NHS Scottish morbidity records (SMR 01, 04, 06) and prescribing records for all participants who have consented and for whom a CHI number is available allowing linkage [$22 000 (92%)] is currently under way. This will allow validation of the self-reported events recorded in the study, and provide information on clinical endpoints and follow-up. The mechanism for governance of these and further linkages has been established and a number of other research proposals involving linkage of study data from selected subsets of the cohort to a range of other NHS data sets have been approved.
In addition, consent for re-contact allows follow-up studies or related research. One study is in the process of doing this, having invited 500 participants to volunteer for further research on stroke; to date, around 150 have responded positively and meet the entry criteria. Several other studies involving re-contact of GS:SFHS participants have been approved and will begin soon.
What has it found?
Baseline epidemiology Baseline clinical results are summarized in Tables 3-5 and Figures 3 and 4 . Based on self-reporting, illnesses 1  3  5  7  9  11  13  15  17  19  21  23  25  2  4  6  8  10  12  14  16  18  20  22 24 Figure 4 Distribution of responses to personality and cognitive function tests were generally less prevalent than in the Scottish population (Table 3) , but were reported more frequently by participating family members than by respondents themselves (Table 4) . Almost half (41%) were taking at least one prescribed medication. From the Rose angina questionnaire, 21 4% of the individuals were classified with a previous possible myocardial infarction, and 4% with possible angina. Only 28% of the former and 23% of the latter reported heart disease in their personal medical history. The cohort tended to be overweight, 21% having body mass index (BMI) 430. BP measurement found 31% to be 'hypertensive' (with systolic BP 4140 mmHg, or diastolic BP 490 mmHg), compared with only 13.7% who self-reported hypertension. Similarly, around 6% of the participants who completed respiratory tests had evidence of COPD (FEV 1 <0.8 of expected value, and FEV 1 /FVC ratio <0.7), 33 whereas only 1.1% self-reported COPD. Analysis of ECGs found that 68% were classified as 'normal', 10% 'abnormal' and 22% with bradycardia.
A history of a single major depressive disorder was diagnosed in 6.6%, and recurrent major depressive disorder in 6.3% (total with major depression 12.9%); the self-reported prevalence was only 6.2%. A further 0.3% were diagnosed with a history of bipolar disorder. Although comparable data for the UK are not available, epidemiological studies in the USA found rates of 17.1% in the national comorbidity survey in 1994 34 and 16.6% in a replication study a decade later. 35 The number (%) who had GHQ 28 scores 44 (indicating potentially significant psychological distress) was 4009 (18.9%) (n ¼ 21 186). The sample was very slightly higher in extraversion, and more markedly lower in neuroticism than the data reported on adults by Eysenck et al. . 36 This provides a basis for seeking the genes involved. Similarly, the heritability of a number of cardiovascular disease (CVD) risk factors and of cognitive function was calculated in the sample, finding that not only were CVD and cognitive function strongly associated but also that these associations were caused predominantly by genetic rather than environmental factors. 37 A genetic analysis found that two variants of the complement receptor 1 gene (cr1), known to be associated with Alzheimer's disease, were also associated with major recurrent depression and with psychological distress, particularly among women. 38 Other analyses of genes associated with depression are completed or under way, including genome-wide association and exome sequencing. GS:SFHS was the largest contributor of cases and controls (n ¼ 5474) to the SpiroMeta consortium that identified and characterized five new genetic variants associated with lung function, three of which (tns, gstcd and htr4) were associated with COPD. 39, 40 GS:SFHS subsequently made the largest contribution (n ¼ 10 399) to the large-scale follow-up (total n ¼ 46 411) of a genome-wide association study that identified 16 further new loci associated with lung function. 41 Serum from participants was used in immunosurveillance of H1N1 influenza exposure, finding that 34% of the Scots had been naturally infected by March 2010, at a peak rate of 4.3 new infections per 1000 people/day. 42 Other studies are under way in a range of clinical areas and will report soon (www. generationscotland.org/collaborations.htm).
What are the main strengths and weaknesses?
GS:SFHS data have been rigorously and robustly collected, on a wide range of clinical parameters, focusing on quantitative traits that are well established as risk factors for disease. The cohort includes substantial numbers representing the full adult spectrum of ages, lifestyle and demography and important phenotypes and quantitative traits to allow population-based genetic and epidemiological research on many important diseases and risks. Data can be linked anonymously to routinely collected NHS data sets, including prescribing records, hospital attendances and admissions and cancer and death registration. 1 This linkage effectively converts this cross-sectional study into a longitudinal study, with pluripotential outcomes.
GS:SFHS can contribute as a major partner to genome-wide association study meta-analysis consortia enabling the study of SNPs of low minor allele frequency (1-10%). [39] [40] [41] Study power increases with sample size and percentage of variance explained, and needs to be estimated for each individual study; however, GS:SFHS is one of the largest family-based genetic epidemiology studies in existence internationally and is well placed to make an important contribution. Besides its size, the family-based approach of GS:SFHS enables the study to take a flexible approach to gene discovery, encompassing association and linkage approaches, and gives the potential to study aspects such as heritability of disease-related traits, and parent-of-origin effects. The combination of linkage and association approaches has proven very effective in studies of various diseases/disease traits, including Crohn's disease and HbF levels, 4 especially where several rarer alleles act at a single locus. The study by Luciano et al. 37 illustrates the combined strengths of family structure and breadth of phenotypes available in GS:SFHS: by incorporating cognitive measures into the analysis, they were able to explain a significant fraction of cardiovascular risk not explained by established factors.
Medical and medication history are self-reported and therefore subject to recall error. We have noted above the discrepancy between measured and self-reported prevalence of hypertension, COPD and depression, though elsewhere it has been shown that there is substantial agreement between self-reporting and actual presence of disease (as confirmed in medical records). 43 Confirmation of much of the information is possible through linkage of the research data with routine NHS data, and further validation of self-reported medical history within our sample is currently under way. Meanwhile, the use of validated objective assessments is recommended where available.
Although the family-based nature of the cohort is an important strength of the study, providing among other things an efficient strategy for DNA sequence-based studies, relatedness of cohort members will be a confounding factor in some analyses, and may require statistical adjustment.
Can I get hold of the data? Where can I find out more?
GS has successfully implemented an access process with high governance standards, to which researchers can submit collaboration proposals. Access to data and samples is governed by the GS access committee, and managed through a web-based procedure (www .gsaccess.org). Anonymized data and/or samples are released if the proposed research is consistent with ethical approval and participant consent, confidentiality, data and sample management, and subsequent publication requirements established in the management, access and publications policy (www. generationscotland.org/access.htm). Researchers and their host institutions sign data and/or material transfer agreements to this effect. The collection is now approved as a tissue bank (reference 10/s1402/20), including ethical approval for all research using the data and samples, within the terms of the original ethical approval and participant consent. GS welcomes research proposals from academic and commercial researchers.
Further information is available at www. generationscotland.org.
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